Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...
Investor's Business Daily on MSN3d
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...
Louis Vuitton owner LVMH reported disappointing results and said it faced challenges in most markets. Shares of both the ...
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment. Read why I upgrade NVCR stock from buy ...
Stock futures traded mildly to the upside Wednesday and tech shares looked set for a slight rebound following a sharp slump ...
The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback